Comments

Coherus Oncology Stock Price, Quotes and Forecasts

Q: What sector and industry does Coherus Oncology (CHRS) operate in?

Coherus Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

CHRSNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$0.7431

At close: Jun 30 EDT

$0.7301

-0.01-1.75%

Pre-Market: 8:00 AM EDT

Coherus Oncology (CHRS) Forecast

News Earnings Coherus Oncology (CHRS) Options Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Coherus Oncology Stock Price, Quotes and Forecasts | NASDAQ:CHRS | Benzinga

Explore Coherus Oncology stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for CHRS.

Open	-
Close	-
Volume / Avg.	44.04K / 1.57M
Day Range	- - -
52 Wk Range	0.66 - 2.43
Market Cap	$84.64M
P/E Ratio	1.68
Dividend Yield	-
Exchange	NASDAQ
RSI	43
Short Interest	28.65%
Days to Cover	24.46

Recent News

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC.

Vandana Singh

Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the price target from $2.1 to $2. CommScope shares dipped 6.9% to $2.2150 on Monday.

Avi Kapoor

Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?

Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncology and will help reduce debt and overhead costs.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Jan

Mar

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	-
Close	-
Volume / Avg.	44.04K / 1.57M
Day Range	- - -
52 Wk Range	0.66 - 2.43
Market Cap	$84.64M
P/E Ratio	1.68
Dividend Yield	-
Exchange	NASDAQ
RSI	43
Short Interest	28.65%
Days to Cover	24.46

About Coherus Oncology Inc.

Sector

Health Care

Industry

Biotechnology

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an appro...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Coherus Oncology (CHRS) stock?

You can purchase shares of Coherus Oncology (NASDAQ:CHRS) through any online brokerage.

View our list of the best stock brokerages

Who are Coherus Oncology (CHRS) competitors?

Other companies in Coherus Oncology’s space includes: Macrogenics (NASDAQ:MGNX), Zentalis Pharma (NASDAQ:ZNTL), Inovio Pharmaceuticals (NASDAQ:INO), Whitehawk Therapeutics (NASDAQ:WHWK) and TScan Therapeutics (NASDAQ:TCRX).

What is the forecast, or price target, for Coherus Oncology (CHRS) stock?

Coherus Oncology has a consensus price target of $9.01.

What is the current price for Coherus Oncology (CHRS)?

The stock price for Coherus Oncology (NASDAQ: CHRS) is $0.7301 last updated June 30, 2025 at 8:00 AM EDT.

Does Coherus Oncology (CHRS) pay a dividend?

There are no upcoming dividends for Coherus Oncology.

When is Coherus Oncology (NASDAQ:CHRS) reporting earnings?

Coherus Oncology’s Q2 earnings are confirmed for Thursday, August 7, 2025.

Is Coherus Oncology (CHRS) going to split?

There is no upcoming split for Coherus Oncology.

What sector and industry does Coherus Oncology (CHRS) operate in?

Coherus Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.